Investment

Four family investment groups back fast-growing nature-based biotech group

A group of family investment groups, along with institutional investors, has invested $150 million in a biotech company using AI and molecules found in nature to develop new therapeutics for the treatment of multiple diseases. 

Subscribe

You will need a Premium+ Subscription to read this article.

Exclusive news, analysis and research on global family enterprise and private investment offices

SUBSCRIBE TODAY

Already have an account? Sign in

You need a Premium subscription.

To read Premium articles please subscribe.

SUBSCRIBE TODAY

Already have an account? Sign in

You've reached the end.

Continue reading free articles by registering as a Member.
Or choose a Premium Plan.

SUBSCRIBE TODAY

Already have an account? Sign in

Leave a Reply